Vyriad Inc. closed a final $25 million tranche of its series B, bringing total series B financing to $85 million to support first‑in‑human testing of VV‑169, an in vivo CAR T candidate targeting relapsed or refractory multiple myeloma. The company said the funds will underwrite IND‑enabling work and the planned clinical entry of the oncolytic‑vector approach. The financing reflects investor appetite for novel in‑body cell programming strategies and provides runway for Vyriad’s clinical milestones. Biotech investors and partnering teams will track the initial clinical protocol and safety readouts, which will be pivotal for follow‑on funding or out‑licensing discussions.